Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer

Background/Objectives: SLFN11 is a regulator of cellular sensitivity to DNA-damaging agents, but its role in non-small-cell lung cancer (NSCLC), particularly in the context of radiochemotherapy, remains incompletely understood. This study aimed to evaluate the association of SLFN11 with chemo- and radiosensitivity in NSCLC cell lines and to explore its potential association with clinical outcome in patients with stage III NSCLC treated with platinum-based radiochemotherapy. Methods: SLFN11 expression was analyzed in a genetically diverse panel of NSCLC cell lines. Transient siRNA-mediated SLFN11 knockdown was performed, followed by carboplatin treatment, irradiation, and combined carboplatin–irradiation treatment. Short-term cell viability was assessed using MTS assays, while long-term survival was evaluated by clonogenic assays. Key findings were validated with a second, independent siRNA pool in two SLFN11-high cell lines, and cell cycle distribution and apoptosis were analyzed by flow cytometry. In addition, SLFN11 protein expression was assessed by immunohistochemistry in pretreatment tumor samples from a small, highly selected retrospective subgroup. Results: SLFN11 expression varied markedly across NSCLC cell lines. SLFN11 knockdown was associated with reduced carboplatin sensitivity in selected models, with the most pronounced effects observed in SLFN11-high cell lines. This finding was reproduced with the second siRNA pool and was accompanied by attenuated carboplatin-induced S-phase accumulation and apoptosis, most consistently in HCC15 cells. In contrast, SLFN11 depletion did not consistently alter radiation response or clonogenic survival after irradiation. Combined carboplatin–irradiation treatment largely reflected the effects observed with carboplatin exposure. In the exploratory clinical subgroup, SLFN11 protein expression was not associated with progression-free survival following platinum-based radiochemotherapy. Conclusions: These findings suggest that SLFN11 is associated with platinum-related short-term cytotoxicity and apoptosis, whereas no consistent effect on intrinsic radiosensitivity or long-term clonogenic survival was observed in the analyzed NSCLC models. The clinical analysis should be interpreted as exploratory and hypothesis-generating. Overall, the relevance of SLFN11 as a biomarker appears to be treatment-context-dependent and requires validation in larger, clinically well-defined cohorts.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223672
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer

Rami Ateyah El Shafie, Hanibal Bohnenberger, Manuel Guhlich, Tobias Raphael Overbeck et al.
Cancers
Lung Cancer Treatments and Mutations
article

Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer

Rami Ateyah El Shafie, Hanibal Bohnenberger, Manuel Guhlich, Tobias Raphael Overbeck, Laura Anna Fischer, Stefan Küffer, Martin Leu, Leif H. Dröge, Stefan Rieken, Alexander Freiherr von Hammerstein-Equord, Friederike Braulke, Niklas Christian Scheele, Lovis Hampe, Anna Luisa Riedl, Lisa-Antonia von Diest, Tim Niemeier, Julian Johannes Reiß
article en

Abstract

Background/Objectives: SLFN11 is a regulator of cellular sensitivity to DNA-damaging agents, but its role in non-small-cell lung cancer (NSCLC), particularly in the context of radiochemotherapy, remains incompletely understood. This study aimed to evaluate the association of SLFN11 with chemo- and radiosensitivity in NSCLC cell lines and to explore its potential association with clinical outcome in patients with stage III NSCLC treated with platinum-based radiochemotherapy. Methods: SLFN11 expression was analyzed in a genetically diverse panel of NSCLC cell lines. Transient siRNA-mediated SLFN11 knockdown was performed, followed by carboplatin treatment, irradiation, and combined carboplatin–irradiation treatment. Short-term cell viability was assessed using MTS assays, while long-term survival was evaluated by clonogenic assays. Key findings were validated with a second, independent siRNA pool in two SLFN11-high cell lines, and cell cycle distribution and apoptosis were analyzed by flow cytometry. In addition, SLFN11 protein expression was assessed by immunohistochemistry in pretreatment tumor samples from a small, highly selected retrospective subgroup. Results: SLFN11 expression varied markedly across NSCLC cell lines. SLFN11 knockdown was associated with reduced carboplatin sensitivity in selected models, with the most pronounced effects observed in SLFN11-high cell lines. This finding was reproduced with the second siRNA pool and was accompanied by attenuated carboplatin-induced S-phase accumulation and apoptosis, most consistently in HCC15 cells. In contrast, SLFN11 depletion did not consistently alter radiation response or clonogenic survival after irradiation. Combined carboplatin–irradiation treatment largely reflected the effects observed with carboplatin exposure. In the exploratory clinical subgroup, SLFN11 protein expression was not associated with progression-free survival following platinum-based radiochemotherapy. Conclusions: These findings suggest that SLFN11 is associated with platinum-related short-term cytotoxicity and apoptosis, whereas no consistent effect on intrinsic radiosensitivity or long-term clonogenic survival was observed in the analyzed NSCLC models. The clinical analysis should be interpreted as exploratory and hypothesis-generating. Overall, the relevance of SLFN11 as a biomarker appears to be treatment-context-dependent and requires validation in larger, clinically well-defined cohorts.

CancersVol. 18(22)
Universitätsmedizin Göttingen (DE), University of Göttingen (DE)
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon